Latest by Treatment Action Group
New research shows that it may be possible to identify many latently infected CD4 T cells due to expression of a particular cell surface protein.
Richard Jefferys analyzes key presentations from this year's Conference on Retroviruses and Opportunistic Infections.
Treatment Action Group Lauds Launch of NYC Sexual Health Clinics as Hubs of Comprehensive HIV Prevention and Care
Amid growing concerns about federal government commitments to the HIV response, the New York City Department of Health is expanding the city's sexual health clinics as hubs of HIV prevention, care and treatment.
HIV cure researchers seek out markers that would allow the specific targeting of cells harboring latent HIV. Enter a new candidate: interferon-induced transmembrane protein 1 (IFITM1).
Community Mobilization: An Assessment of Mechanisms and Barriers at Community-Based and AIDS Service Organizations in Nine U.S. Metropolitan Areas
A new report shines a spotlight on the need for more investments in community leadership and mobilization to end HIV as an epidemic.
"The results of the study appear very encouraging, and the researchers are hoping to rapidly evaluate whether they have any relevance to humans," Richard Jefferys writes. "A small clinical trial of the anti-α4β7 antibody vedolizumab, which is FDA-app...
Viekira Pak is a combination of hepatitis C (HCV) drugs paritaprevir, ritonavir, ombitasvir and dasabuvir, approved for people over 18 with HCV genotype 1. Technivie is a combination of paritaprevir, ritonavir and ombitasvir, approved for people ove...
Harvoni (sofosbuvir/ledipasvir) is a combination tablet approved for adults with hepatitis C genotypes 1, 4, 5, and 6, with or without cirrhosis. It is also approved to treat HCV in people living with HIV.
Sovaldi (sofosbuvir) is a hepatitis C (HCV) drug currently approved for people with HCV genotypes 1, 2, 3, or 4 who are over 18 years old.